Post-earnings recap
Reported
Wed, Dec 11, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
Twist Bioscience's earnings report showed a loss per share that was in line with expectations, but the stock rose by nearly 4%. This increase may reflect investor confidence in the company's long-term strategy and ongoing investments, despite the lack of revenue details and guidance updates.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.96 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism about the company's future. They emphasized their commitment to innovation and growth.
Management highlighted ongoing investments in technology and product development.
They expressed confidence in long-term growth despite current challenges.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—